Evusheld (Cilgavimab | Tixagevimab)

Evusheld is a long-acting antibody combination used for COVID-19 prevention. It contains cilgavimab and tixagevimab, manufactured by AstraZeneca AB in the EU.

Evusheld is designed to help prevent COVID-19 in certain individuals. It is administered via intramuscular injection and is intended for those who may not mount an adequate immune response to vaccination. The combination of cilgavimab and tixagevimab works to target the SARS-CoV-2 virus, aiming to provide protection against infection.

Common effects of Evusheld may include reactions at the injection site, such as pain or swelling. Some individuals might experience general symptoms like fatigue or headache. These effects are typically mild and temporary.

Evusheld should be used under the guidance of a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions before administration. Proper storage and handling are crucial to maintain the efficacy of the medication.

Evusheld may interact with other medications, particularly those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of Evusheld.